EUREPA 1MG TABLET 15'S

EUREPA 1MG TABLET 15'S starts working 30 minutes after it has been taken. After you take EUREPA 1MG TABLET 15'S, the insulin levels increase causing a decrease in the blood sugar levels. The effect usually lasts for 4 hours.

No, you should avoid alcohol while taking EUREPA 1MG TABLET 15'S since alcohol interferes with the working of EUREPA 1MG TABLET 15'S. You may experience signs and symptoms of low blood sugar levels which include weakness, shakiness, cold sweat, cool pale skin, rapid heartbeat, tremors, extreme hunger, dizziness, headache, and anxiety.

Yes, it can be taken with other antidiabetic drugs but according to your doctor’s advice. But since all these drugs lower blood sugar levels, regular monitoring of blood sugar levels is recommended.

No, you should not breastfeed your baby because if EUREPA 1MG TABLET 15'S passes in breast milk, your baby may experience low blood sugar levels which is harmful to your baby. Ask your doctor for advice.

You should inform your doctor and take his advice. If you cannot avoid using clopidogrel with EUREPA 1MG TABLET 15'S, take 0.5 mg EUREPA 1MG TABLET 15'S before each meal. The total daily dose should not be more than 4 mg. Monitor your blood sugar levels more frequently.

Eurepa 1, which contains repaglinide 1 mg, is used to help control blood sugar levels in adults with type 2 diabetes mellitus. It is prescribed when diet, exercise, and weight reduction alone are not sufficient to achieve adequate glycemic control. It helps reduce mainly post‑meal blood sugar spikes and is usually part of a broader diabetes management plan that includes lifestyle changes and regular monitoring.

Eurepa 1 belongs to a group of medicines called meglitinides. It works by stimulating the beta cells of the pancreas to release insulin in response to meals. This insulin release helps lower blood sugar levels, especially after eating. Its action is relatively short‑acting and closely related to meal timing, which is why it is generally taken shortly before main meals, as directed by the doctor.

Eurepa 1 should be used with caution in patients with liver impairment because repaglinide is primarily metabolized in the liver. In people with moderate to severe liver disease, the medicine may accumulate and increase the risk of side effects, particularly hypoglycemia. The doctor may decide to avoid its use or use it at a lower strength or with closer monitoring, depending on the severity of liver dysfunction. Patients with known liver disease must inform their healthcare provider before starting Eurepa 1.

Eurepa 1 can sometimes be used in patients with mild to moderate kidney impairment, but it requires careful medical supervision. Reduced kidney function can alter the way the body handles medicines and may increase the risk of low blood sugar. In severe kidney disease, the doctor may choose alternative treatments or adjust therapy based on individual risk–benefit assessment. Patients with any degree of kidney problems should not take Eurepa 1 without explicit guidance from their nephrologist or diabetologist.

The safety of Eurepa 1 (repaglinide) during pregnancy has not been well established. Insulin is generally preferred for managing diabetes in pregnant women because it has a more established safety profile. If you are pregnant, planning to become pregnant, or suspect you might be pregnant, you must inform your doctor before using Eurepa 1. Your doctor will evaluate the potential benefits and risks and may switch you to insulin or another regimen considered safer in pregnancy.

It is not clearly known whether repaglinide, the active ingredient in Eurepa 1, passes into breast milk. Because of the potential risk of hypoglycemia in the nursing infant and the limited safety data, Eurepa 1 is generally not the first choice during breastfeeding. Your doctor may recommend alternative treatments, often insulin, or may advise you on whether to discontinue breastfeeding or change your diabetes medication. Always discuss breastfeeding plans with your healthcare provider before starting or continuing Eurepa 1.

Eurepa 1 can cause hypoglycemia, which may lead to symptoms such as dizziness, confusion, blurred vision, or difficulty concentrating. These symptoms can impair your ability to drive or operate machinery safely. If you experience signs of low blood sugar, you should avoid driving or using heavy machines until your blood sugar is corrected and you feel fully recovered. Patients who have frequent episodes of hypoglycemia or reduced awareness of low blood sugar should discuss driving safety with their doctor.

Alcohol can unpredictably affect blood sugar levels and may increase the risk of hypoglycemia when taken with Eurepa 1. Drinking alcohol on an empty stomach, skipping meals, or consuming large amounts of alcohol can be particularly risky. If your doctor allows moderate alcohol intake, it should be limited, taken with food, and your blood sugar should be monitored closely. Chronic heavy alcohol use is generally discouraged in people with diabetes and may further complicate the safe use of Eurepa 1.

If you have a known allergy to repaglinide, any component of Eurepa 1, or have experienced serious allergic reactions to similar antidiabetic medicines in the past, you should not take Eurepa 1. Signs of an allergic reaction can include rash, itching, swelling of the face, lips, or throat, severe dizziness, or difficulty breathing. If any of these occur after taking Eurepa 1, seek emergency medical help immediately and do not take further doses. Always inform your doctor and pharmacist about all your allergies before starting this medicine.

Yes, hypoglycemia (low blood sugar) is a common and important side effect of Eurepa 1. It is more likely to occur if you skip or delay meals, eat less than usual, exercise more than normal, drink alcohol, or use Eurepa 1 with other blood sugar‑lowering medicines. Symptoms include sweating, shakiness, hunger, palpitations, headache, irritability, confusion, or blurred vision. If you experience these, check your blood sugar if possible and take fast‑acting carbohydrates such as glucose tablets, sugar, or sweet juice as advised by your healthcare provider. Seek medical help if symptoms are severe or do not improve. Your doctor will guide you on individualized hypoglycemia management.

No, Eurepa 1 is not suitable for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. These conditions require insulin therapy and urgent medical management. Eurepa 1 relies on functioning pancreatic beta cells to stimulate insulin release, which are absent or severely deficient in type 1 diabetes. If you have type 1 diabetes or develop symptoms of ketoacidosis such as excessive thirst, frequent urination, nausea, vomiting, abdominal pain, or rapid breathing, seek immediate medical attention and do not rely on Eurepa 1.